吸附无细胞百白破-灭活脊髓灰质炎(Sabin株)-b型流感嗜血杆菌结合疫苗(DPT-IPV-Hib)在≥2且<43月龄健康日本婴儿中的免疫原性与安全性:一项III期、多中心、阳性对照、评估者盲法、随机、平行组研究
本研究为III期多中心随机对照试验,纳入267名≥2且<43月龄健康日本婴儿,比较五联疫苗DPT-IPV-Hib单剂与Hib疫苗(ActHIB®)联合四联疫苗(Tetrabik)分别接种的免疫原性与安全性。主要终点为初次免疫后抗PRP抗体≥1 μg/mL的阳性率及百日咳、白喉、破伤风、脊髓灰质炎抗体阳性率,结果显示试验组对所有测量抗体均非劣效于对照组,两组GMT在加强免疫后均升高,未发现安全性问题。
要点
- 初次免疫后抗PRP抗体≥1 μg/mL阳性率:DPT-IPV-Hib组100.0% vs Hib+DPT-IPV组88.7%。
- 白喉毒素抗体阳性率:DPT-IPV-Hib组99.2% vs Hib+DPT-IPV组98.5%;破伤风毒素抗体阳性率:100.0% vs 99.2%。
- 百日咳和减毒脊髓灰质炎病毒抗体阳性率两组均为100.0%,所有测量抗体均证实非劣效。
核心结论
- 单剂Gobik(日本首个获批的DPT-IPV-Hib五联疫苗)可同时提供针对Hib感染、百日咳、白喉、破伤风及脊髓灰质炎的基础和加强免疫,其预防效果和安全性可与Hib疫苗(ActHIB®)联合DPT-IPV四联疫苗(Tetrabik)接种相媲美。
研究设计与样本
- III期、多中心、阳性对照、评估者盲法、随机、平行组研究;267名随机参与者(DPT-IPV-Hib组133名,Hib+DPT-IPV组134名)接受共4剂皮下接种(3剂基础免疫和1剂加强免疫)。
主要发现
- 基础免疫后,DPT-IPV-Hib组 vs Hib+DPT-IPV组的抗PRP抗体≥1 μg/mL阳性率分别为100.0%和88.7%,白喉毒素抗体阳性率分别为99.2%和98.5%,破伤风毒素抗体阳性率分别为100.0%和99.2%,百日咳和减毒脊髓灰质炎病毒抗体阳性率两组均为100.0%;DPT-IPV-Hib组对所有测量抗体均非劣效于Hib+DPT-IPV组;两组基础免疫后所有抗体GMT均高于首剂前,加强免疫后GMT均高于基础免疫后;未发现安全性问题。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study investigated the immunogenicity and safety of a pentavalent vaccine Gobik (DPT-IPV-Haemophilus influenzae type b [Hib]) in healthy Japanese infants aged ≥ 2 and < 43 months using a concomitant vaccination with ActHIB® (Hib) and Tetrabik (DPT-IPV) as a comparator. METHODS: This study was conducted as a phase 3, multicenter, active controlled, assessor-blinded, randomized, parallel-group study. Participants received a total of 4 subcutaneous doses (3 primary immunization doses and a booster dose) of either the experimental drug (DPT-IPV-Hib) or the active comparator (Hib + DPT-IPV). The primary endpoints were the anti-PRP antibody prevalence rate with ≥ 1 μg/mL, and the antibody prevalence rates against pertussis, diphtheria toxin, tetanus toxin, and attenuated poliovirus after the primary immunization. RESULTS: In 267 randomized participants (133 in the DPT-IPV-Hib group and 134 in the Hib + DPT-IPV group), the antibody prevalence rates after the primary immunization in both groups were 100.0 % and 88.7 % for anti-PRP antibody with ≥ 1 μg/mL, 99.2 % and 98.5 % against diphtheria toxin, and 100.0 % and 99.2 % against tetanus toxin, respectively. The antibody prevalence rates against pertussis and attenuated poliovirus were 100.0 % in both groups. The non-inferiority of the DPT-IPV-Hib group to the Hib + DPT-IPV group was verified for all measured antibodies. In both groups, all the GMTs of antibodies after the primary immunization were higher than those before the first dose, and those after the booster dose were higher than those after the primary immunization. No safety issues were identified. CONCLUSION: A single-agent Gobik, the first DPT-IPV-Hib pentavalent vaccine approved in Japan, was confirmed to simultaneously provide primary and booster immunizations against Hib infection, pertussis, diphtheria, tetanus, and poliomyelitis and to have a preventive effect and safety comparable to concomitant vaccination with Hib (ActHIB®) and DPT-IPV quadrivalent vaccine (Tetrabik).
引用
- Nakano T, Hasegawa M, Endo M, et al. Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants ≥ 2 and < 43 months of Age: A phase III, multicenter, active controlled, assessor-blinded, randomized, parallel-group study. Vaccine. 2024. PMID: 38582691. doi:10.1016/j.vaccine.2023.03.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。